Background. FeNO has been used as a marker for Th2-mediated airway inflammation in asthma. There is evidence which recommends the use of this biomarker in asthma management. Little is known about whether the FeNO test alone or in combination with the ACT score can reflect asthma control in Vietnamese patients. Materials and Methods. A cross-sectional study was conducted in asthmatic patients (≥18 years old) recruited at the University Medical Center, Ho Chi Minh City, Vietnam from March 2016 to March 2017. Asthma control levels were assessed following the GINA 2017 guidelines, and FeNO was measured by a Niox Mino device. FeNO cut-offs predicting asthma control status were determined using the ROC curve analysis. The combination of FeNO and ACT was investigated in detecting well-controlled and uncontrolled asthma. The results of the study are as follows: 278 patients with 68% females, mean age of 44 years, and mean asthma duration of 10 years were analyzed. All patients were treated following step 2 to 4 of GINA guidelines. Mean (SD) FeNO was 30.6 (24) ppb. Patients with uncontrolled (16%), partly controlled (29%), and well-controlled asthma (55%) had a median (IQR) FeNO of 50.0 (74), 25.0 (23), and 21.0 (22.3) ppb, respectively, and the mean of FeNO in the uncontrolled group was significantly higher than that in other groups (p<0.001). The area under the ROC curve (AUC) for FeNO detecting uncontrolled asthma was 0.730 with an optimal cut-off point of FeNO > 50 ppb, and this AUC increased to 0.89 when combining FeNO and ACT. The AUC for FeNO detecting well-controlled asthma was 0.601 with an optimal cut-off point of FeNO <25 ppb and this AUC increased to 0.78 if combining FeNO and ACT. Conclusions. FeNO can predict asthma control status with an estimated cut-off point of <25 ppb for well-controlled and >50 ppb for uncontrolled asthma. The combination of FeNO and ACT provides better information regarding asthma control than FeNO alone, and this combination is useful to predict asthma control statuses in asthmatic patients in Viet Nam.
Background: FeNO has been used as a marker for airway infammation, although controversy persists on its clinical utility in asthma management. The relationship between FeNO levels, asthma control plus asthma severity in Vietnamese patients has not previously been reported. Methods: Cross-sectional study conducted in asthmatic patients ≥ 18 years old in Ho Chi Minh City, from 3/2015-3/2017. Asthma control and severity were assessed using GINA 2017 criteria, and the relationship with FeNO (Niox Mino) was assessed. FeNO cutoffs predicting asthma control status were determined using receiver operating characteristic (ROC) curve analysis. Results: 278 asthmatic patients with 68% female and mean age 44 years, mean asthma duration 10 years. Mean (SD) FeNO was 30.6 (24) parts per billion (ppb).Patients with uncontrolled (16%), partlycontrolled (29%) and well-controlled asthma (55%) had mean (SD) FeNO was 56 (40), 26.4 (16) and 25.7 (17) ppb, respectively, and these means were significantly different (p<0.001). Patients with mild (12%), moderate (17%) and severe asthma (45%) had mean (SD) FeNO was 23.1(17), 31.1 (25) and 29.2. (23) ppb, respectively and these means were not significantly different (p=0.3). The area under the ROC curve (AUC) for the FeNO predicting uncontrolled asthma was 0.730 (95% CI: 0.637-0.823) with optimal cutoff point of FeNO>50 ppb. The AUC for detecting well-controlled asthma was 0.601 (95% CI: 0.534-0.668) with optimal cutoff point of FeNO <25 ppb. Conclusions: FeNO level was not related to GINA defined asthma severity but statistically related to asthma control status and can predict uncontrolled and well-controlled asthma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.